Inventor · disambiguated record

Weikang Tao

Also filed as: TAO WEIKANG

50 granted patents·72 pending applications·100 citations·filing 2010–2025

97Inventor score

Technology areasC07K A61K C07D A61P C12N

Files withJIANGSU HENGRUI MEDICINE CO75 JIANGSU HENGRUI PHARMACEUTICALS CO LTD35 SUZHOU SUNCADIA BIOPHARMACEUTICALS CO LTD6 Shanghai hengrui pharmaceutical co ltd2 HANSOH SHANGHAI HEALTHTECH CO LTD1

Top patents by PatentIndex Score

122 records

0194US12227499B2Fused imidazole derivative, preparation method therefor, and medical use thereofJIANGSU HENGRUI PHARMACEUTICALS CO LTD·Filed 2021·Granted Feb 18, 2025·4 cites·18 claims
0294US10905743B2Interleukin 15 protein complexJIANGSU HENGRUI MEDICINE CO·Filed 2015·Granted Feb 2, 2021·9 cites·10 claims
0392US12202891B2Antibody capable of binding to thymic stromal lymphopoietin and use thereofJIANGSU HENGRUI MEDICINE CO·Filed 2024·Granted Jan 21, 2025·2 cites·9 claims
0492US10633375B2Oxopicolinamide derivative, preparation method therefor and pharmaceutical use thereofJIANGSU HENGRUI MEDICINE CO·Filed 2017·Granted Apr 28, 2020·6 cites·21 claims
0592US10344090B2PD-1 antibody, antigen-binding fragment thereof, and medical application thereofShanghai hengrui pharmaceutical co ltd·Filed 2014·Granted Jul 9, 2019·15 cites·27 claims
0691US11717559B2Interleukin 15 protein complex and use thereofJIANGSU HENGRUI MEDICINE CO·Filed 2020·Granted Aug 8, 2023·2 cites·15 claims
0790US12258394B2IL-5 antibody, antigen binding fragment thereof, and medical application thereforJIANGSU HENGRUI MEDICINE CO·Filed 2022·Granted Mar 25, 2025·1 cites·13 claims
0890US10206980B2IL-15 heterodimeric protein and uses thereofShanghai hengrui pharmaceutical co ltd·Filed 2014·Granted Feb 19, 2019·20 cites·19 claims
0989US10786567B2Stable anti-PD-1 antibody pharmaceutical preparation and application thereof in medicineSUZHOU SUNCADIA BIOPHARMACEUTICALS CO LTD·Filed 2016·Granted Sep 29, 2020·4 cites·18 claims
1087US10543284B2Anti-c-Met antibody and anti-c-Met antibody-cytotoxic drug conjugate and pharmaceutical use thereofSUZHOU SUNCADIA BIOPHARMACEUTICALS CO LTD·Filed 2016·Granted Jan 28, 2020·6 cites·36 claims
1186US11365255B2PD-1 antibody, antigen-binding fragment thereof, and medical application thereofSUZHOU SUNCADIA BIOPHARMACEUTICALS CO LTD·Filed 2019·Granted Jun 21, 2022·2 cites·12 claims
1285US12473279B2Fused imidazole derivative, preparation method therefor, and medical use thereofJIANGSU HENGRUI PHARMACEUTICALS CO LTD·Filed 2024·Granted Nov 18, 2025·0 cites·6 claims
1384US11274142B2Fusion protein containing TGF-β receptor and medicinal uses thereofJIANGSU HENGRUI MEDICINE CO·Filed 2018·Granted Mar 15, 2022·3 cites·16 claims
1483US10815304B2PD-L1 antibody, antigen-binding fragment thereof and medical application thereofSUZHOU SUNCADIA BIOPHARMACEUTICALS CO LTD·Filed 2016·Granted Oct 27, 2020·3 cites·25 claims
1582US10906905B2Five-membered heteroaryl ring bridged ring derivative, preparation method therefor and medical use thereofJIANGSU HENGRUI MEDICINE CO·Filed 2017·Granted Feb 2, 2021·2 cites·20 claims
1681US12428478B2Anti-Claudin 18.2 antibody and application thereofJIANGSU HENGRUI MEDICINE CO·Filed 2020·Granted Sep 30, 2025·1 cites·17 claims
1781US11359021B2PD-L1 antibody, antigen-binding fragment thereof, and pharmaceutical use thereofJIANGSU HENGRUI MEDICINE CO·Filed 2019·Granted Jun 14, 2022·2 cites·20 claims
1881US10442793B2Oxa spiro derivative, preparation method therefor, and applications thereof in medicinesJIANGSU HENGRUI MEDICINE CO·Filed 2016·Granted Oct 15, 2019·2 cites·24 claims
1980US11111249B2Heteroaryl-pyrazole derivative, and preparation method therefor and medical application thereofJIANGSU HENGRUI MEDICINE CO·Filed 2018·Granted Sep 7, 2021·3 cites·15 claims
2079US10449250B2Anti-sclerostin antibody, antigen binding fragment and medical use thereofJIANGSU HENGRUI MEDICINE CO·Filed 2016·Granted Oct 22, 2019·2 cites·20 claims
2178US12459937B2Fused imidazole derivative, preparation method therefor, and medical use thereofJIANGSU HENGRUI PHARMACEUTICALS CO LTD·Filed 2025·Granted Nov 4, 2025·0 cites·20 claims
2278US11512055B2Benzimidazole derivatives as modulators of retinoid-related orphan receptor gamma (RORγ) and pharmaceutical uses thereofJIANGSU HENGRUI MEDICINE CO·Filed 2019·Granted Nov 29, 2022·1 cites·2 claims
2378US11365247B2IL-5 antibody, antigen binding fragment thereof, and medical application thereforJIANGSU HENGRUI MEDICINE CO·Filed 2018·Granted Jun 21, 2022·1 cites·12 claims
2478US11117898B2Pyrazolo-heteroaryl derivative, preparation method and medical use thereofJIANGSU HENGRUI MEDICINE CO·Filed 2017·Granted Sep 14, 2021·3 cites·23 claims
2575US10889569B2Condensed ring group azacyclobutyl triazole derivative, preparation method therefor and use thereof in medicineJIANGSU HENGRUI MEDICINE CO·Filed 2017·Granted Jan 12, 2021·1 cites·20 claims
2673US12258405B2CD3 antibody and pharmaceutical use thereofJIANGSU HENGRUI MEDICINE CO·Filed 2019·Granted Mar 25, 2025·1 cites·14 claims
2773US11535633B2Fused tricyclic heterocycle compounds and therapeutic uses thereofJIANGSU HENGRUI MEDICINE CO·Filed 2019·Granted Dec 27, 2022·2 cites·33 claims
2873US11345753B2TIM-3 antibody, antigen binding fragment thereof, and medicinal uses thereofJIANGSU HENGRUI MEDICINE CO·Filed 2018·Granted May 31, 2022·1 cites·18 claims
2971US2025282773A1Fused imidazole derivative, preparation method therefor, and medical use thereofJIANGSU HENGRUI PHARMACEUTICALS CO LTD·Filed 2025·Application pending·0 cites
3070US12187684B2Benzimidazole derivatives as modulators of retinoid-related orphan receptor gamma (RORγ) and pharmaceutical use thereofJIANGSU HENGRUI MEDICINE CO·Filed 2022·Granted Jan 7, 2025·0 cites·18 claims
3170US11312705B2Heteroaryl[4,3-C]pyrimidine-5-amine derivative, preparation method therefor, and medical uses thereofJIANGSU HENGRUI MEDICINE CO·Filed 2018·Granted Apr 26, 2022·1 cites·16 claims
3269US11981733B2LAG-3 antibody, antigen-binding fragment thereof, and pharmaceutical application thereofJIANGSU HENGRUI MEDICINE CO·Filed 2021·Granted May 14, 2024·0 cites·20 claims
3368US2025333494A1Il-5 antibody, antigen binding fragment thereof, and medical application thereforJIANGSU HENGRUI MEDICINE CO·Filed 2025·Application pending·0 cites
3466US12404323B2Antibody capable of binding to thymic stromal lymphopoietin and use thereofJIANGSU HENGRUI MEDICINE CO·Filed 2020·Granted Sep 2, 2025·0 cites·9 claims
3566US11084808B2Oxopicolinamide derivative, preparation method therefor and pharmaceutical use thereofJIANGSU HENGRUI MEDICINE CO·Filed 2020·Granted Aug 10, 2021·0 cites·8 claims
3665US10899837B2B7-H3 antibody, antigen-binding fragment thereof and medical use thereofJIANGSU HENGRUI MEDICINE CO·Filed 2018·Granted Jan 26, 2021·0 cites·17 claims
3764US2025270303A1Anti-abeta antibody, antigen-binding fragment thereof and application thereofJIANGSU HENGRUI MEDICINE CO·Filed 2025·Application pending·0 cites
3864US2025376519A1Antigen-binding molecule specifically binding to dll3 and cd3, and pharmaceutical use thereofJIANGSU HENGRUI PHARMACEUTICALS CO LTD·Filed 2023·Application pending·0 cites
3962US12325741B2Anti-Aβ antibodies and antigen-binding fragments thereofJIANGSU HENGRUI MEDICINE CO·Filed 2019·Granted Jun 10, 2025·0 cites·10 claims
4062US11155617B2LAG-3 antibody, antigen-binding fragment thereof, and pharmaceutical application thereofJIANGSU HENGRUI MEDICINE CO·Filed 2017·Granted Oct 26, 2021·0 cites·21 claims
4162US2025057968A1Anti-dll3 antibody and pharmaceutical use thereof, and antibody-drug conjugate containing anti-dll3 antibodyJIANGSU HENGRUI PHARMACEUTICALS CO LTD·Filed 2022·Application pending·0 cites
4262US2021380593A1Pyrazolo-heteroaryl derivative, preparation method and medical use thereofJIANGSU HENGRUI MEDICINE CO·Filed 2021·Application pending·0 cites
4361US11680100B2B7-H3 antibody, antigen-binding fragment thereof and medical use thereofHANSOH SHANGHAI HEALTHTECH CO LTD·Filed 2020·Granted Jun 20, 2023·0 cites·17 claims
4461US2025043022A1Antigen-binding molecule specifically binding to psma and cd3, and pharmaceutical use thereofJIANGSU HENGRUI PHARMACEUTICALS CO LTD·Filed 2023·Application pending·0 cites
4560US2025197390A1Fused heterocyclic compound, and preparation method therefor and medical use thereofJIANGSU HENGRUI PHARMACEUTICALS CO LTD·Filed 2023·Application pending·0 cites
4660US2024270874A1Anti-klb antibodies and usesJIANGSU HENGRUI PHARMACEUTICALS CO LTD·Filed 2022·Application pending·0 cites
4760US2024352132A1Antigen-binding molecule specifically binding to hgfr and egfr, and pharmaceutical use thereofJIANGSU HENGRUI PHARMACEUTICALS CO LTD·Filed 2022·Application pending·0 cites
4860US2024400670A1Anti-il23 antibody fusion protein and uses thereofJIANGSU HENGRUI PHARMACEUTICALS CO LTD·Filed 2022·Application pending·0 cites
4959US11780923B2PD-L1 antibody, antigen-binding fragment thereof and medical application thereofSUZHOU SUNCADIA BIOPHARMACEUTICALS CO LTD·Filed 2020·Granted Oct 10, 2023·0 cites·23 claims
5059US2025122211A1Nitrogen-containing tetracyclic compound, preparation method therefor, and medical use thereofJIANGSU HENGRUI PHARMACEUTICALS CO LTD·Filed 2022·Application pending·0 cites

Showing the top 50 of 122 patent records by PatentIndex Score.

Join the waitlist — get patent alerts

Get an alert when Weikang Tao files or is granted a new patent.

We store only your email — no account needed. See our privacy policy.

Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →